Literature DB >> 3004341

Heparin modulates conformational states of plasma fibronectin: an electron spin resonance spin label approach.

E G Ankel, G Homandberg, N M Tooney, C S Lai.   

Abstract

We have examined the interaction between heparin and human plasma fibronectin using electron spin resonance (ESR) spin label methods. The titratable sulfhydryl groups of plasma fibronectin were modified with a maleimide spin label [Lai and Tooney (1984) Arch. Biochem. Biophys. 228, 465-473]. Addition of heparin resulted in a decrease in the maximum splitting value of the ESR spectrum of spin-labeled fibronectin from 66.8 to 64.3 G, suggesting that heparin induces a conformational alteration of plasma fibronectin. This heparin effect was noticeable at a heparin-to-fibronectin ratio of 20 to 1 and reached a plateau at about 100 to 1. Other sulfated carbohydrates were tested; dextran sulfate was found to be as effective as heparin but chondroitin sulfates were ineffective. The results presented suggest that the binding of heparin changes the molecular conformation of plasma fibronectin to a more relaxed or flexible state.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3004341     DOI: 10.1016/0003-9861(86)90093-7

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  3 in total

1.  Matrix-driven translocation: dependence on interaction of amino-terminal domain of fibronectin with heparin-like surface components of cells or particles.

Authors:  S A Newman; D A Frenz; E Hasegawa; S K Akiyama
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

2.  A synthetic peptide from the COOH-terminal heparin-binding domain of fibronectin promotes focal adhesion formation.

Authors:  A Woods; J B McCarthy; L T Furcht; J R Couchman
Journal:  Mol Biol Cell       Date:  1993-06       Impact factor: 4.138

3.  Models of fibronectin.

Authors:  M Rocco; E Infusini; M G Daga; L Gogioso; C Cuniberti
Journal:  EMBO J       Date:  1987-08       Impact factor: 11.598

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.